← The Wire
ZYMENasdaq
Zymeworks Inc.
Pharmaceutical Preparations · DE · CIK 1937653
Zymeworks develops novel biotherapeutics for difficult-to-treat diseases and manages licensed healthcare assets
$1.68B
Market cap
$24.10
Last close
-0.2%
1D
+3.6%
5D
1.1M
Volume
Price · last 39 sessions-10.0%
May 4L $22.49 · H $27.61Jun 29
120
Total filings
Jun 29, 2026
Last filing
12/31
Fiscal year end
8-KMaterial Agreement · Reg FD DisclosureJun 29, 20268-KReg FD Disclosure · Company UpdateMay 14, 202610-Q10-QMay 7, 20268-KResults of Operations · Reg FD DisclosureMay 7, 20268-KExecutive ChangeApr 1, 20268-KMaterial Agreement · New Debt / ObligationMar 2, 202610-K10-KMar 2, 20268-KResults of Operations · Reg FD DisclosureMar 2, 20268-KExecutive Change · Results of OperationsJan 12, 20268-KShareholder VoteDec 30, 20258-KExecutive Change · Reg FD DisclosureNov 18, 20258-KCompany UpdateNov 17, 2025DEFA14ADEFA14ANov 10, 2025DEF 14ADEF 14ANov 10, 202510-Q10-QNov 6, 20258-KResults of Operations · Reg FD DisclosureNov 6, 20258-KReg FD Disclosure · Company UpdateSep 2, 20258-KExecutive Change · Material AgreementAug 11, 202510-Q10-QAug 7, 20258-KResults of Operations · Reg FD DisclosureAug 7, 20258-KMaterial Agreement · Equity IssuanceJun 27, 20258-KReg FD Disclosure · Company UpdateMay 30, 202510-Q10-QMay 8, 20258-KResults of Operations · Reg FD DisclosureMay 8, 202510-K10-KMar 5, 20258-KResults of Operations · Reg FD DisclosureMar 5, 20258-KExecutive Change · Company UpdateFeb 18, 20258-KResults of Operations · Company UpdateJan 8, 20258-KShareholder Vote · Company UpdateDec 11, 20248-KReg FD Disclosure · Company UpdateNov 21, 2024SC 13GSC 13GNov 13, 202410-Q10-QOct 31, 20248-KResults of Operations · Reg FD DisclosureOct 31, 2024DEFA14ADEFA14AOct 29, 2024DEF 14ADEF 14AOct 29, 20248-KExecutive Change · Company UpdateOct 18, 20248-KExecutive ChangeSep 3, 20248-KMaterial AgreementAug 2, 2024424B5424B5Aug 2, 20248-KReg FD Disclosure · Company UpdateAug 1, 202410-Q10-QAug 1, 20248-KResults of Operations · Reg FD DisclosureAug 1, 20248-KExecutive ChangeJul 25, 20248-KCompany UpdateJun 10, 20248-KCompany UpdateMay 3, 2024424B5424B5May 3, 2024424B5424B5May 3, 202410-Q10-QMay 2, 20248-KResults of Operations · Reg FD DisclosureMay 2, 20248-KExecutive ChangeApr 4, 20248-KExecutive ChangeApr 1, 20248-KExecutive Change · Company UpdateMar 28, 202410-K10-KMar 6, 20248-KResults of OperationsMar 6, 2024SC 13DSC 13DFeb 22, 20248-KExecutive ChangeFeb 22, 20248-KExecutive Change · Company UpdateFeb 8, 2024SC 13GSC 13GJan 29, 20248-KExecutive ChangeJan 5, 20248-KResults of Operations · Company UpdateJan 4, 20248-KMaterial Agreement · Equity IssuanceDec 26, 20238-KShareholder Vote · Company UpdateDec 8, 202310-Q10-QNov 7, 20238-KResults of OperationsNov 7, 20238-KAgreement TerminatedNov 2, 2023DEFA14ADEFA14AOct 26, 2023DEF 14ADEF 14AOct 26, 20238-KExecutive Change · Company UpdateOct 16, 20238-KAgreement Terminated · Company UpdateSep 21, 202310-Q10-QAug 10, 20238-KResults of OperationsAug 10, 20238-KExecutive Change · Company UpdateJun 29, 20238-KSecurity-Holder Rights · Bylaw AmendmentJun 12, 20238-KCompany UpdateJun 5, 20238-KExecutive ChangeMay 18, 20238-KMaterial AgreementMay 16, 2023424B5424B5May 8, 2023424B5424B5May 8, 20238-KResults of OperationsMay 8, 202310-Q10-QMay 8, 2023
Insider Activity
In the 90 days to Jan 12, 2026: 4 sold $4.7M.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Jan 12, 2026 | Galbraith KennethChair & CEO | Sell | 30,424 | $22.67 | $690K |
| Jan 12, 2026 | Moore Paul AndrewChief Scientific Officer | Sell | 9,560 | $22.67 | $217K |
| Jan 12, 2026 | Smith Jeffrey T LEVP & Chief Medical Officer | Sell | 9,310 | $22.67 | $211K |
| Jan 12, 2026 | Hollywood MarkEVP & Chief Operating Officer | Sell | 6,120 | $22.67 | $139K |
| Jan 5, 2026 | Galbraith KennethChair & CEO | Sell | 31,686 | $25.10 | $795K |
| Jan 5, 2026 | Galbraith KennethChair & CEO | Sell | 22,657 | $25.10 | $569K |
| Jan 5, 2026 | Moore Paul AndrewChief Scientific Officer | Sell | 10,821 | $25.10 | $272K |
| Jan 5, 2026 | Smith Jeffrey T LEVP & Chief Medical Officer | Sell | 10,538 | $25.10 | $265K |
| Jan 5, 2026 | Moore Paul AndrewChief Scientific Officer | Sell | 9,289 | $25.10 | $233K |
| Dec 22, 2025 | Galbraith KennethChair & CEO | Sell | 47,528 | $27.02 | $1.3M |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.
Similar companies
Comparable business profile · signals at a glance